Anti-Therapeutic Action: contraindicated in psychotic disorders

Psilocybin-assisted therapy for severe alcohol use disorder: protocol for a double-blind, randomized, placebo-controlled, 7-month parallel-group phase II superiority trial

mycolabadmin

This study tests whether psilocybin (the active compound in magic mushrooms) combined with therapy can help people with severe alcohol addiction reduce drinking. Participants receive either a high or low dose of psilocybin during a guided session as part of a hospital rehabilitation program. The researchers will measure changes in drinking behavior, mood, anxiety, and brain function to determine if this treatment works better than current options.

Read More »

Psilocybin-induced modulation of visual salience processing

mycolabadmin

When people take psilocybin mushrooms, they look at images differently – they focus more on visually striking regions while keeping their eyes in smaller areas. Brain recordings showed changes in electrical activity patterns. The research suggests psilocybin alters how the brain balances what naturally catches attention versus where we intentionally choose to look.

Read More »

Study protocol for ‘Psilocybin in patients with fibromyalgia: brain biomarkers of action’

mycolabadmin

Researchers are testing whether psilocybin (the active compound in magic mushrooms) combined with therapeutic support can help people with fibromyalgia, a chronic pain condition. The study will measure brain activity using EEG and brain imaging to understand how psilocybin might reduce pain and improve mental health. Twenty patients will receive guided psilocybin sessions over eight weeks while researchers track changes in brain function and pain levels.

Read More »
Scroll to Top